Otitis Treatment with OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
- Conditions
- Otitis Media Acute
- Interventions
- Device: OtoSight Middle Ear Scope
- Registration Number
- NCT06285812
- Lead Sponsor
- PhotoniCare, Inc.
- Brief Summary
A pragmatic, mixed-method trial is to show the ability of OtoSight to change management of the pediatric patient presenting with ear pain in a way that improves patient outcomes and reduces costs.
- Detailed Description
Mixed method, multi-center, pragmatic, cluster-randomized effectiveness-implementation investigation focused on pediatric subjects presenting with ear complaints at the office setting.
For the prospective randomized component, eligible clinicians at a given site will be randomized to one of two groups: the OtoSight intervention group or the usual care control group. There will be three (3) periods of post-intervention assessment: 10 days (optional), 6 months, and 12 months.
Eligible subjects will be automatically enrolled (or invited to enroll) in the clinical trial and will receive information. Because this is a non-interference design, frontline care clinicians randomized to either arm will be asked to: (1) assess the presence or absence of fluid in the middle ear; (2) record a diagnosis; and (3) treat the patient as they would according to the information available to them.
A separate retrospective historical matched control arm will also be conducted to analyze potential Hawthorne effect at a subset of collaborating practices or healthcare systems. Randomization of clinicians (and not children) will decrease contamination in the usual practice group (i.e., so clinicians are not asked to flip between intervention and usual care practices).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 700
- Pediatric subjects between 6 months and 17 years of age
- Pediatric subjects presenting for an office visit with ear-related pain (otalgia)/otic complaints/earache indicative of potential Otitis Media with Effusion (OME) or Acute Otitis Media (AOM)
- Pediatric subjects where otoscopy would traditionally be indicated
- Pediatric subjects whose parents or legally authorized representative (LAR) have signed an informed consent
- The parent or guardian who attends visits does not speak the same language as their physician
- Pediatric subjects enrolled in another clinical trial
- Pediatric subjects with:
- Signs of severe chronic illness (e.g., immunodeficiency, congenital heart disease, encephalopathy, pulmonary disease other than asthma, and disorder of the ear, nose and throat) or any clinically significant illness or condition that, in the opinion of the investigator, would prohibit the subject from participating in the trial
- Anatomical conditions that would affect their ability to undergo an otoscopy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description OtoSight #1 OtoSight Middle Ear Scope Prospective Randomized Control Trial (RCT) OtoSight #2 OtoSight Middle Ear Scope Case and provider match
- Primary Outcome Measures
Name Time Method Change the number of antibiotic rounds per patient Baseline to 12 month Follow Up Antibiotic stewardship
Change the clinician rate of antibiotic prescriptions Baseline to 12 month Follow Up Antibiotic stewardship
Change costs associated with management of pediatric patients presenting with ear-related pain Baseline to 21 month Follow Up Change in overall costs
- Secondary Outcome Measures
Name Time Method Change in unnecessary antibiotic prescriptions Baseline to 12 month Follow Up Change in unnecessary antibiotic prescriptions based on reported diagnosis and treatment recommendations of providers
Change in prescription adherence Baseline to 12 month Follow Up Change in prescription adherence
Change medical resource utilization Baseline to 30 days Follow Up Change in follow-up visit frequency, ENT (Ear, Nose, and Throat) referral frequency
Impact clinician confidence Baseline to 12 month Follow Up Change in clinician confidence scores reported on Provider CRF
Improve patient outcomes Baseline to 12 month Follow Up Change in progression to recurrent AOM (rAOM) based on tracking provider diagnoses
Change in Health-related Quality of Life (HQoL) Baseline to 12 month Follow Up Change in HQoL scores reported on the OMO-22 and OM-6
Change in antibiotic prescription rate when fluid not present Baseline to 12 month Follow Up Change in antibiotic prescriptions rate when fluid is not present based on reported treatment recommendations of providers
Impact caregiver satisfaction Baseline to 12 month Follow Up Change in clinician satisfaction scores reported on Provider CRF
Change unnecessary medical intervention Baseline to 12 month Follow Up Change in amount of unnecessary medical intervention (e.g., tympanostomy tube surgeries) based on tracking provider treatment recommendations and diagnoses
Trial Locations
- Locations (7)
Abba Medical Group LLC
🇺🇸Miami, Florida, United States
AdventHealth Children's Research
🇺🇸Orlando, Florida, United States
HealthStar Physicians
🇺🇸Morristown, Tennessee, United States
Children's National Hospital
🇺🇸Washington, District of Columbia, United States
Trillim Health
🇺🇸Rochester, New York, United States
Cyn3rgy Research
🇺🇸Gresham, Oregon, United States
Carolina ENT
🇺🇸Orangeburg, South Carolina, United States